Sangamo BioSciences | SGMO - Operating Expenses


Sangamo BioSciences reported $33.87M in Operating Expenses for its fiscal quarter ending in June of 2024.





Operating Expenses Change Date
Alaunos Therapeutics USD 1.01M 175K Mar/2026
Alnylam Pharmaceuticals USD 1.06B 160.97M Jun/2026
Alterity Therapeutics Limited AUD 8.67M 893.38K Dec/2025
Amgen USD 11.69B 6.9B Jun/2026
Bayer EUR 10.04B 168M Jun/2026
BioCryst Pharmaceuticals USD 119.78M 673.63M Jun/2026
Biogen USD 2.98B 1.02B Jun/2026
BioMarin Pharmaceutical USD 6.32B 5.69B Jun/2026
Cipla INR 62.31B 3.04B Jun/2026
Clal Biotechnology ILS 5.15M 9.47M Dec/2022
Compugen USD 11.19M 96K Mar/2026
CSL USD 5.7B 2.82B Dec/2025
Gilead Sciences USD 3.95B 19.57B Jun/2026
GlaxoSmithKline GBP 5.8B 468M Jun/2026
Grifols EUR 1.99B 217.4M Dec/2025
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
J&J USD 18.93B 1.09B Sep/2026
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
Merck USD 15.77B 2.4B Jun/2026
Novartis USD 10.2B 912M Jun/2026
Omeros USD 59.16M 20.13M Jun/2024
Pfizer USD 85.19B 4.91B Jun/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sanofi EUR 9.92B 607M Jun/2026
Sarepta Therapeutics USD 387.96M 15.59M Jun/2026
Tectonic Therapeutic USD 27.3M 5.78M Mar/2026
Ultragenyx Pharmaceutical USD 289M 16M Jun/2026
Vertex Pharmaceuticals USD 2.07B 217.1M Jun/2026